News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,042 Results
Type
Article (41805)
Company Profile (329)
Press Release (662908)
Section
Business (210124)
Career Advice (2074)
Deals (36571)
Drug Delivery (96)
Drug Development (82795)
Employer Resources (171)
FDA (16476)
Job Trends (15356)
News (355381)
Policy (33818)
Tag
Academia (2574)
Alliances (51080)
Alzheimer's disease (1246)
Approvals (16407)
Artificial intelligence (140)
Bankruptcy (362)
Best Places to Work (11668)
Biotechnology (214)
Breast cancer (122)
Cancer (1103)
Cardiovascular disease (102)
Career advice (1737)
Cell therapy (236)
Clinical research (65771)
Collaboration (393)
Compensation (199)
COVID-19 (2601)
C-suite (96)
Data (1128)
Diabetes (154)
Diagnostics (6223)
Earnings (86502)
Employer resources (149)
Events (112304)
Executive appointments (316)
FDA (17018)
Funding (352)
Gene therapy (186)
GLP-1 (609)
Government (4444)
Healthcare (18850)
Infectious disease (2685)
Inflammatory bowel disease (110)
Interviews (319)
IPO (16573)
Job creations (4050)
Job search strategy (1487)
Layoffs (433)
Legal (8318)
Lung cancer (172)
Manufacturing (185)
Medical device (13259)
Medtech (13264)
Mergers & acquisitions (20062)
Metabolic disorders (418)
Neuroscience (1530)
NextGen Class of 2024 (6624)
Non-profit (4512)
Northern California (1483)
Obesity (240)
Opinion (203)
Patents (104)
People (58222)
Pharmaceutical (92)
Phase I (20341)
Phase II (28946)
Phase III (21711)
Pipeline (456)
Postmarket research (2643)
Preclinical (8673)
Radiopharmaceuticals (240)
Rare diseases (228)
Real estate (6240)
Regulatory (22360)
Research institute (2357)
Resumes & cover letters (358)
Southern California (1304)
Startups (3711)
United States (13577)
Vaccines (567)
Weight loss (182)
Date
Today (140)
Last 7 days (830)
Last 30 days (3806)
Last 365 days (36160)
2024 (33141)
2023 (40628)
2022 (51798)
2021 (56331)
2020 (54795)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (199)
Asia (39984)
Australia (6393)
California (3334)
Canada (1292)
China (252)
Colorado (146)
Connecticut (154)
Europe (85137)
Florida (458)
Georgia (116)
Illinois (347)
Indiana (204)
Kansas (96)
Maryland (580)
Massachusetts (2639)
Michigan (158)
Minnesota (272)
New Jersey (965)
New York (956)
North Carolina (716)
Northern California (1483)
Ohio (138)
Pennsylvania (846)
South America (1157)
Southern California (1304)
Texas (469)
Washington State (365)
705,042 Results for "oric pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
ORIC Pharmaceuticals to Participate in Upcoming June 2024 Investor Conferences
ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in June.
May 29, 2024
·
1 min read
Biotech Bay
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
ORIC Pharmaceuticals, Inc. announced that on June 3, 2024, ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.
June 7, 2024
·
5 min read
Press Releases
ORIC® Pharmaceuticals to Participate in Upcoming November 2024 Investor Conferences
November 5, 2024
·
1 min read
Press Releases
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
November 13, 2024
·
9 min read
Business
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2024.
May 6, 2024
·
9 min read
Drug Development
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications.
April 15, 2024
·
7 min read
Biotech Bay
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
ORIC Pharmaceuticals, Inc. announced that on May 1, 2024, ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024.
May 3, 2024
·
5 min read
Biotech Bay
ORIC Pharmaceuticals to Participate in Upcoming April 2024 Investor Conferences
ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in April.
April 4, 2024
·
1 min read
Biotech Bay
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
ORIC Pharmaceuticals, Inc. announced that on April 1, 2024, ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.
April 5, 2024
·
5 min read
Biotech Bay
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals, Inc. today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
April 8, 2024
·
8 min read
1 of 70,505
Next
